ALXO: ALX Oncology Net earnings per share (EPS TTM)

ALX Oncology Holdings (ALXO) - corporate logo

The 12-month profit per share level demonstrates the growth dynamics of ALX Oncology (ALXO), which rely on the readiness of research centers and production capacity reserves. This parameter reaches -0.88, correlating with the potential for global market reach driven by patents. Meanwhile, the safety of CD47 inhibitors in gastric cancer therapy without blood toxicity remains the key success factor.

ALXO ALX Oncology Net earnings per share for the last 12 months (07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for ALX Oncology Holdings Inc. (ALXO)

- share price and expert price forecast:
Fundamental valuation:ALXO - alxoncology.com
Flagship merchandise of ALX Oncology

Fundamental analysis of EPS TTM allows for risk minimization by assessing the real return of each share. For ALX Oncology Holdings (ALXO), which develops unique oncology blockers, this metric reflects the efficiency of capitalizing on future pricing power. The calculation of this metric excludes the influence of capital structure, making the company's trailing twelve-month earnings per share an accurate indicator of operational resilience. This chart demonstrates the business's adaptation to cost inflation, which determines the fair value of the assets.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)